SEC Sues Former Invitrogen Official for Insider Trading | GenomeWeb
NEW YORK (GenomeWeb News) - The US Securities and Exchange Commission late last month sued a former Invitrogen official for allegedly trading stock on insider knowledge in 2004, GenomeWeb Daily News has learned.
In its complaint, the SEC accuses Harry Yim of sparing himself $80,000 in losses and profiting to the tune of $410,000 by selling shares in Invitrogen soon after the company was informed in a July 7, 2004, meeting that it is in a “crisis” and that “fully 60 percent of Invitrogen’s business is shrinking.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.